Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immuneering Corp

1.29
+0.05004.03%
Pre-market: 1.340.0451+3.50%08:40 EDT
Volume:140.87K
Turnover:182.96K
Market Cap:46.29M
PE:-0.63
High:1.34
Open:1.23
Low:1.23
Close:1.24
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

Company Profile

Company Name:
Immuneering Corp
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
66
Office Location:
245 Main Street,Second Floor,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
- -
Introduction:
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Directors

Name
Position
Benjamin J. Zeskind
Co-Founder, President, Chief Executive Officer, Director
Robert J. Carpenter
Chairman and Director
Ann E. Berman
Director
Diana F. Hausman
Director
Laurie B. Keating
Director
Peter Feinberg
Director

Shareholders

Name
Position
Benjamin J. Zeskind
Co-Founder, President, Chief Executive Officer, Director
Brett Hall
Chief Scientific Officer
Harold E. Brakewood
Chief Business Officer
Leah R. Neufeld
Chief People Officer
Mallory Morales
Vice President, Finance and Treasurer
Michael D. Bookman
Chief Legal Officer, Secretary
Scott Barrett
Chief Medical Officer

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."